文献速递胸部肿瘤

ALEX研究中ALK阳性NSCLC患者按中心IHC或FISH检测的ALK状态分层的结局

Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.
PubMed 文献 · J Thorac Oncol · 2020-10-24

该研究回顾性分析ALEX研究中303例初治晚期ALK IHC阳性NSCLC患者,按中心FISH状态分层比较阿来替尼与克唑替尼的PFS和缓解率。结果显示IHC阳性/FISH阳性及FISH不确定患者中阿来替尼显著优于克唑替尼,而FISH阴性患者未见获益。提示Ventana ALK IHC可作为选择阿来替尼治疗的标准检测方法。

要点

  • IHC阳性/FISH阳性患者中阿来替尼较克唑替尼显著延长PFS(HR=0.37)。
  • IHC阳性/FISH不确定患者中阿来替尼同样显著延长PFS(HR=0.39)。
  • IHC阳性/FISH阴性患者中阿来替尼未见PFS获益(HR=1.33)。

核心结论

  • 在ALEX研究中,ALK IHC阳性且FISH阳性或FISH不确定的NSCLC患者,阿来替尼疗效与总体人群相似。
  • ALK IHC阳性但FISH阴性的患者未显示阿来替尼优于克唑替尼。
  • 结果支持Ventana ALK IHC作为选择阿来替尼治疗患者的标准检测方法。

研究设计与样本

  • 回顾性分析III期ALEX研究,共303例初治晚期ALK IHC阳性NSCLC患者随机接受阿来替尼600mg每日两次或克唑替尼250mg每日两次。
  • ALK状态采用中心Ventana ALK(D5F3)CDx IHC和Vysis ALK Break Apart FISH探针试剂盒评估。
  • 主要终点为研究者评估的PFS,次要终点包括客观缓解率和缓解持续时间。

主要发现

  • IHC阳性/FISH阳性患者(n=203,67%)中,阿来替尼较克唑替尼显著延长PFS(HR=0.37,95%CI:0.25-0.56;p<0.0001)。
  • IHC阳性/FISH不确定患者(n=61,20%)中,阿来替尼较克唑替尼显著延长PFS(HR=0.39,95%CI:0.20-0.78)。
  • IHC阳性/FISH阴性患者(n=39,13%)中,PFS无显著差异(HR=1.33,95%CI:0.6-3.2)。
  • IHC阳性/FISH阳性患者中,阿来替尼组客观缓解率90.6% vs 克唑替尼组81.4%(分层OR=2.22,95%CI:0.97-5.07)。
  • IHC阳性/FISH不确定患者中,阿来替尼组客观缓解率96.0% vs 克唑替尼组75.0%(OR=9.29,95%CI:1.05-81.88)。

关键数值与推荐

  • IHC阳性/FISH阳性患者中阿来替尼组客观缓解率90.6%,克唑替尼组81.4%(分层OR=2.22,95%CI:0.97-5.07)。
  • IHC阳性/FISH不确定患者中阿来替尼组客观缓解率96.0%,克唑替尼组75.0%(OR=9.29,95%CI:1.05-81.88)。
  • IHC阳性/FISH阴性患者中阿来替尼组客观缓解率28.6%,克唑替尼组44.4%(OR=0.45,95%CI:0.12-1.74)。
  • 39例IHC阳性/FISH阴性患者中35例接受二代测序,20例(57.1%)未检出ALK融合,其中10例(50.0%)达到部分缓解或疾病稳定。

临床怎么用

  • 对于晚期NSCLC,可依据Ventana ALK IHC阳性结果选择阿来替尼治疗,无需常规依赖FISH。
  • IHC阳性但FISH阴性的患者阿来替尼获益不明确,需结合二代测序等其他方法综合评估。

局限性

  • 本研究为回顾性分析,FISH亚组样本量较小(尤其FISH阴性组仅39例)。
  • FISH阴性组中二代测序仅部分患者完成,解读需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We retrospectively examined progression-free survival (PFS) and response by ALK fluorescence in situ hybridization (FISH) status in patients with advanced ALK immunohistochemistry (IHC)-positive NSCLC in the ALEX study. METHODS: A total of 303 treatment-naive patients were randomized to receive twice-daily alectinib 600 mg or crizotinib 250 mg. ALK status was assessed centrally using Ventana ALK (D5F3) CDx IHC and Vysis ALK Break Apart FISH Probe Kit. Primary end point is investigator-assessed PFS. Secondary end points of interest are objective response rate and duration. RESULTS: Investigator-assessed PFS was significantly prolonged with alectinib versus crizotinib in ALK IHC-positive and FISH-positive tumors (n = 203, 67%) (hazard ratio [HR] = 0.37, 95% confidence interval [CI]: 0.25-0.56; p < 0.0001) and ALK IHC-positive and FISH-uninformative tumors (n = 61, 20%) (HR = 0.39, 95% CI: 0.20-0.78) but not in ALK IHC-positive and FISH-negative tumors (n = 39, 13%) (HR = 1.33, 95% CI: 0.6-3.2). Objective response rates were higher with alectinib versus crizotinib in ALK IHC-positive and FISH-positive tumors (90.6% versus 81.4%; stratified OR = 2.22, 95% CI: 0.97-5.07) and ALK IHC-positive and FISH-uninformative tumors (96.0% versus 75.0%; OR = 9.29, 95% CI: 1.05-81.88) but not in ALK IHC-positive and FISH-negative tumors (28.6% versus 44.4%; OR = 0.45, 95% CI: 0.12-1.74). Next-generation sequencing was performed in 35 of 39 patients with ALK IHC-positive and FISH-negative tumors; no ALK fusion was identified in 20 of 35 patients (57.1%) by next-generation sequencing, but 10 of 20 (50.0%) had partial response or stable disease. CONCLUSIONS: Outcomes of patients with ALK IHC-positive and FISH-positive and ALK IHC-positive and FISH-uninformative NSCLC were similar to those of the overall ALEX population. These results suggest that Ventana ALK IHC is a standard testing method for selecting patients for treatment with alectinib.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Mok T, Peters S, Camidge DR, et al. Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. J Thorac Oncol. 2020. PMID: 33334571. doi:10.1016/j.jtho.2020.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。